Pharmacokinetics and ECG Effects of Linaprazan Glurate in Erosive Gastroesophageal Reflux Disease: A Phase I Study in Healthy Subjects

The primary objective of this Phase I trial is to evaluate the **pharmacokinetics** and **ECG effects** of single doses of linaprazan glurate when administered as oral tablets to healthy participants. This investigation is clinically relevant as it aims to understand the absorption, distribution, metabolism, and excretion of linaprazan glurate, as well as its potential impact on cardiac electrical activity, which is crucial for assessing the safety profile of the drug. The study is conducted in the context of **Erosive Gastroesophageal Reflux Disease (eGERD)**, a condition characterized by the inflammation and erosion of the esophageal lining due to acid reflux.

The clinical trial involves participants diagnosed with **Erosive Gastroesophageal Reflux Disease (eGERD)**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the **pharmacokinetics** and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants. This study is a Phase I trial focusing on the treatment of **Erosive Gastroesophageal Reflux Disease (eGERD)**. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on July 13, 2022, to the anticipated end date on May 30, 2025.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a control. Subsequent follow-up visits will be scheduled to monitor the participants' response to the treatment, collect pharmacokinetic data, and assess any ECG changes. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data on the investigational product's effects.

The expected length of participant involvement in the trial is determined by the study protocol, which outlines the schedule of visits and assessments. Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to comply with the study protocol, or withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on the administration of other medicinal products or their role in the trial.

Due to the lack of available data, further information on drug administration, dosing schedules, and participant compliance monitoring cannot be described. The absence of these details limits the ability to provide a comprehensive overview of the treatments involved in the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 13, 2022, with an estimated completion date of May 30, 2025. The efficacy of the intervention will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The analysis will be conducted using scientifically validated methods appropriate for a Phase 3 trial. The trial's objective is to provide robust data on the efficacy of the intervention under investigation, contributing to the understanding of its potential benefits in the targeted medical condition.